Ophthalmology

Three patients continue to show improvements in BCVA 3 years post-treatment.

With advancements happening at unprecedented rates, these are the cell and gene therapy companies and pipelines we’re keeping a close eye on.

Investigators found that bilaterally treated participants experienced greater improvements in BCVA than unilaterally treated participants.

The OPTIC phase 1 study showed that the treatment was associated with a significant reduction in treatment burden after 1 injection.

The announcement follows positive results from the phase 1/2a trial of MCO-010 for RP.

Cynata Therapeutics' Ross Macdonald, PhD, discusses the company's pipeline and clinical-phase trials.

Investigators find approach improved vision and visual fields in some patients.

The chief scientific officer and chief medical officer at Eyevensys discuss the biotech company's pipeline and approach to gene therapy.

Detailed data from the phase 3 trial, including safety findings, which were in line with previous studies, will be presented at a future scientific meeting.

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

The chief medical officer of Eyevensys discussed the company’s work in developing sustained drug delivery systems.

RGX-314 may be a promising therapeutic option for exudative AMD.

An overview of new gene therapy options for wet AMD that are currently being explored in clinical trials.

Locanabio CEO James Burns, PhD, discusses the firm's targeted approach to treating genetic disorders of the central nervous system and the eye.

Nanoscope Therapeutics Inc. expects to advance the therapy by launching a late-stage Phase 2b trial this summer with gene therapy that delivers multi-characteristic opsin to retinal cells.

According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.

OpRegen led to restoration of retinal tissue for 75% of patients with dry AMD and geographic atrophy who received the treatment across a wide area of atrophy.

Ross Macdonald, PhD, managing director and CEO of Cynata Therapeutics, discusses the biotech company's approach to overcoming reproducibility challenges with mesenchymal stem cells.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

Maria A. Croyle, PhD, discusses the development of a novel film matrix that can safely and effectively store and transport AAV-based gene therapies.

An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.

Maria A. Croyle, PhD, discusses the manufacturing challenges facing the gene therapy space and her inspiration for developing a novel preservation method for viral vector-based therapies.

Locanabio CEO James Burns, PhD, shares his outlook on the quickly changing landscape of gene therapy research.

Although the XIRIUS study did not meet its primary end point, positive trends were observed across several clinically relevant prespecified secondary end points.

Preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.